

**Remarks**

**I. The Office Action**

**The April 10, 2006 final Office Action (the "Office Action") in this application:**

- 1.) rejected claims 31-35, 37 and 38 under 35 U.S.C. 102(a); and
- 2.) objected to claim 36.

Applicants respond as follows.

II. Cancelled Claim 36

Claim 36 is hereby cancelled without prejudice or disclaimer to future prosecution at a later date.

III. Rejection of claims 31-35, 37 and 38 under 35 U.S.C. 102(b)

The Office Action rejected claims 31-35, 37 and 38 under 35 U.S.C. 102(b) as being anticipated by Barwood et al. (Developmental Medicine & Child Neurology 42, 116-121 (February 2000) ("Barwood").

Claim 36 was not rejected over Barwood.

Solely and in order to facilitate prosecution, independent claims 31 and 38 have been amended to recite all the limitations of cancelled claim 36.

Since the limitations of non-rejected claim 36 have been incorporated into all the rejected claims, the rejection has been overcome and, the rejection should therefore be withdrawn.

IV. Objection of claim 36

The Office Action objects to claim 36 because the claim is dependent from rejected claim 31. Claim 36 has been cancelled and its limitations incorporated into claims 31 and 38, and therefore the objection is overcome.

For this reason, the objection to claim 36 should be withdrawn.

V. Conclusion

All issues raised in the final Office Action have been addressed. Examination and allowance of claims 31-35 and 37-38 is requested.

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.

Respectfully submitted,  
/Claude L. Nassif/

Date: September 29, 2006

Claude L. Nassif, Ph.D.  
Registration Number 52,061

Address all inquiries and correspondence to:

Claude L. Nassif, Ph.D.  
Allergan, Inc., Legal Department  
2525 Dupont Drive, T2-7H  
Irvine, CA 92612  
Telephone: 714 246 6458  
Fax: 714 246 4249